American Thoracic Society, 2025
EFZO-FIT™, the Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis
American Thoracic Society, 2025
Real-World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement
American Thoracic Society, 2025
A Human Histidyl-tRNA Synthetase Splice Variant Therapeutic Targets NRP2 to Resolve Lung Inflammation and Fibrosis
Nangle LA, Xu Z, Siefker D, Burkart C, Chong YE, Zhai L, Geng Y, Polizzi C, Guy L, Eide L, Tong Y, Klopp-Savino S, Ferrer M, Rauch K, Wang A, Hamel K, Crampton S, Paz S, Chiang K, Do M, Burman L, Lee D, Zhang M, Ogilvie K, King D, Adams RA, Schimmel P.
Science Translational Medicine (2025)
Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis
Obi ON, Baughman RP, Crouser ED, Julian, MW, Locke, LW, Chandrasekaran A, Ramesh P, Kinnersley N, Niranjan V, Culver DA, Sporn PHS
European Respiratory Journal (2024)
Efzofitimod is an Immunomodulator of Myeloid Cell Function and Novel Therapeutic Candidate for Interstitial Lung Diseases
American Thoracic Society, 2024
Efzofitimod Promotes Macrophages with Anti-inflammatory Profile via Neuropilin-2 Receptor
Keystone Symposia: Myeloid Cell Diversity, 2024
Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
American College of Rheumatology, 2023
Exposure-Response Analyses of Efzofitimod in Patients With Pulmonary Sarcoidosis
Frontiers in Pharmacology, 2023
Therapeutic Doses of Efzofitimod Significantly Improve Multiple Pulmonary Sarcoidosis Efficacy Measures
European Respiratory Society, 2023